
Sotera Health Company SHC
$ 16.29
0.59%
Quarterly report 2026-Q1
added 05-05-2026
Sotera Health Company DSO Ratio 2011-2026 | SHC
Annual DSO Ratio Sotera Health Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.9 | 47.8 | 46.3 | 41.2 | 21.2 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.8 | 21.2 | 40.1 |
Quarterly DSO Ratio Sotera Health Company
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.6 | 40.9 | 41 | 46.3 | 40.6 | 38.7 | 42.2 | 40.9 | 40.5 | 47.1 | - | 20.5 | 19.6 | 43 | - | 43.3 | 38.9 | 40.5 | - | 41.9 | 39.3 | 22.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 47.1 | 19.6 | 38.6 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | ||
|
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 201.91 | -0.57 % | $ 22.4 B | ||
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
94.7 | $ 3.9 | -9.09 % | $ 5.19 M | ||
|
Castle Biosciences
CSTL
|
50.2 | $ 20.48 | -1.06 % | $ 594 M | ||
|
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
72.7 | - | -61.36 % | $ 2.46 M | ||
|
Fulgent Genetics
FLGT
|
87 | $ 18.53 | -0.8 % | $ 570 M | ||
|
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M | ||
|
Guardant Health
GH
|
46.1 | $ 128.84 | -2.11 % | $ 16.2 B | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 22.91 | -0.26 % | $ 1.22 B | ||
|
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | ||
|
Interpace Biosciences
IDXG
|
66.9 | $ 1.65 | 3.12 % | $ 7.3 M | ||
|
ICON Public Limited Company
ICLR
|
63.4 | $ 146.88 | 0.48 % | $ 11.5 B | ||
|
Illumina
ILMN
|
66.8 | $ 163.68 | 1.68 % | $ 25.4 B | ||
|
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | ||
|
Lantheus Holdings
LNTH
|
80.5 | $ 103.39 | -1.08 % | $ 6.98 B | ||
|
Charles River Laboratories International
CRL
|
65 | $ 190.49 | 1.59 % | $ 9.44 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 470.34 | 0.64 % | $ 13.6 B | ||
|
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | ||
|
Mettler-Toledo International
MTD
|
66.4 | $ 1 148.0 | 1.46 % | $ 23.7 B | ||
|
Myriad Genetics
MYGN
|
52.3 | $ 4.23 | -2.31 % | $ 392 M | ||
|
NeoGenomics
NEO
|
77.7 | $ 11.03 | -1.12 % | $ 1.41 B | ||
|
National Research Corporation
NRC
|
29.4 | $ 18.5 | -1.57 % | $ 414 M | ||
|
Natera
NTRA
|
48.3 | $ 213.73 | 0.78 % | $ 29.2 B | ||
|
Pacific Biosciences of California
PACB
|
71.8 | $ 1.35 | 3.05 % | $ 405 M | ||
|
Personalis
PSNL
|
63.8 | $ 9.78 | 1.98 % | $ 873 M | ||
|
Senseonics Holdings
SENS
|
1.04 | $ 7.26 | 1.04 % | $ 303 M | ||
|
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
27 | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
57.7 | $ 2.03 | -1.22 % | $ 4.66 M | ||
|
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 265.4 | -0.29 % | $ 22.1 B | ||
|
Thermo Fisher Scientific
TMO
|
70 | $ 471.72 | 0.61 % | $ 178 B | ||
|
Trinity Biotech plc
TRIB
|
87.2 | $ 0.65 | -0.26 % | $ 233 M | ||
|
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
44.5 | $ 78.53 | 3.09 % | $ 4.7 B | ||
|
Neogen Corporation
NEOG
|
66.6 | $ 9.19 | 0.99 % | $ 1.99 B | ||
|
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M |